LIDDS participates in BIO International Convention 2023

Non Regulatory

UPPSALA, SWEDEN – LIDDS AB (publ) announces today that the company will participate in BIO International Convention, also known as US BIO, between the 5 and 8 June 2023.

LIDDS’s CEO Anders Månsson will participate in US BIO, which is physically organized in Boston, USA. US BIO is the world's largest meeting place for companies in the pharmaceutical and biotechnology sectors and provides opportunities for both collaboration and partner discussions as well as investor meetings. In total, more than 14,000 participants and 400 presenting companies will gather during the four days.

For additional information, please contact

Anders Månsson, CEO
Phone: +46 (0)70 860 47 38
E-mail: anders.mansson@liddspharma.com
 
Jenni Björnulfson, CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS’s Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

Attachments

LIDDS participates in BIO International Convention 2023